Clinical studies with solvent detergent-treated products

被引：23

作者：

Pehta, JC

机构：

[1] Melville Biologics Inc., New York, NY 10021

来源：

TRANSFUSION MEDICINE REVIEWS | 1996年 / 10卷 / 04期

关键词：

D O I：

10.1016/S0887-7963(96)80006-X

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：303 / 311

页数：9

共 39 条

[1]

ADDIEGO JE, 1992, THROMB HAEMOSTASIS, V67, P19

[2] HUMAN PARVOVIRUS-B19 INFECTION IN HEMOPHILIACS 1ST INFUSED WITH 2 HIGH-PURITY, VIRALLY ATTENUATED FACTOR-VIII CONCENTRATES [J].

AZZI, A ;

CIAPPI, S ;

ZAKVRZEWSKA, K ;

MORFINI, M ;

MARIANI, G ;

MANNUCCI, PM .

AMERICAN JOURNAL OF HEMATOLOGY, 1992, 39 (03) :228-230

[3]

BERNTORP E, 1993, THROMB HAEMOSTASIS, V70, P768

[4]

DIPAOLANTONIO T, 1992, J MED VIROL, V36, P71, DOI 10.1002/jmv.1890360202

[5] TOLERABILITY AND KINETICS OF A SOLVENT-DETERGENT-TREATED INTRAVENOUS IMMUNOGLOBULIN PREPARATION IN HYPOGAMMAGLOBULINEMIA PATIENTS [J].

EBELING, F ;

BAER, M ;

HORMILA, P ;

JARVENTIE, G ;

KOISTINEN, P ;

KATKA, K ;

OKSANEN, K ;

PERKKIO, M ;

RUUTU, T ;

SOPPI, E ;

VEIJOLA, L ;

MYLLYLA, G .

VOX SANGUINIS, 1995, 69 (02) :91-94

[6] TRI(N-BUTYL) PHOSPHATE DETERGENT TREATMENT OF LICENSED THERAPEUTIC AND EXPERIMENTAL BLOOD DERIVATIVES [J].

EDWARDS, CA ;

PIET, MPJ ;

CHIN, S ;

HOROWITZ, B .

VOX SANGUINIS, 1987, 52 (1-2) :53-59

[7]

*FIBR SEAL, 1994, CHAR CLIN US, P34

[8] FDA PERSPECTIVE ON AND RESPONSE TO THE RISK OF HEPATITIS-A FROM BLOOD PRODUCTS [J].

FRICKE, W .

VOX SANGUINIS, 1994, 67 :16-18

[9] VIRUS-INACTIVATED FACTOR-VIII CONCENTRATE PREVENTS POSTOPERATIVE BLEEDING IN A PATIENT WITH VONWILLEBRANDS DISEASE [J].

FURLAN, M ;

LAMMLE, B ;

AEBERHARD, A ;

KIRSTE, E ;

SULZER, I .

TRANSFUSION, 1988, 28 (05) :489-492

[10]

GOMPERTS E, 1991, M NAT HEM FDN TAMP F

← 1 2 3 4 →